AstraZeneca vaccine, which is known to be negotiating with Korea, was found to be more effective when it was given a small amount.
It is a little different from Pfizer vaccines, modders, and vaccines, but medical reporter Cho Dong-chan will explain in detail why it is so and what is advantageous.
AstraZeneca vaccine is a part of the protrusion-shaped and spike protein used when the Corona 19 virus penetrates the cells in the body, and put it inside the adenovirus, which has greatly weakened its power.
When the vaccine enters the body, the spike protein in adenovirus, which causes high fever and respiratory problems, is released, inducing an immune response.
However, at this time, the immune response to adenovirus, which acts as a carrier in our body, also occurs, but if the dose is too large, this immune response mainly occurs, and the immune response to the corona protein may decrease.
In other words, it responds primarily to corona proteins at low doses and adenoviruses at high doses.
This is why the first dose of the twice-shot AstraZeneca vaccine was given at a lower dose and was more effective than the higher dose.
In addition, in addition to antibody immunity at low doses, T immune cell responses were also confirmed.
A recent study at the University of California in the U.S. showed that T cell immunity in response to COVID-19 lasted for at least 6 months, meaning that it may last longer than Pfizer's or Modena's vaccine, which primarily induces antibody immunity.
The company plans to announce the final results for phase 3 clinical trials next month, and says it can produce 200 million doses per month as mass production is also possible.
If the effectiveness is high at low capacity, the production volume is expected to increase and the domestic reserves are expected to increase.
(Source: Korea AstraZeneca)
▶'Astra' is being produced in Korea...
Three vaccine candidates, at which stage?